Earnings Call: Q2 2021

Aug 17, 2021

Good morning, Swadikar. Welcome to the 2nd quarter analyst presentation for BHP CL. As is the usual case for this presentation format, we will begin with an overview by Neil Sorrentino, our Chief Global Strategist. In this quarter, following that, we will be the financial presentation by Koen Jitima, our Deputy CFO. And following on that, a number of business updates, which will be presented by myself and Koen Wissut, our Chief Digital Martech Officer. Without further ado, I'd like to hand this over to Neil, please. Good day together. My name is Neil Sorrentino, Chief Global Strategist for the company. We welcome you to the Q2222021 Takeaways for Bomingrad Public Company Limited. For the quarter, we're going to take a little bit different tact for the Q2 presentation. I've asked our staff to give a much deeper dive into the composition of the data that is driving our revenue. As you have seen already, the quarter was a significantly stronger quarter than Q1 2021 and of course, much stronger than Q2 2020 because that was the peak of the beginning of the COVID impact all over Thailand. The theme for us over the last really 15 months has been agility, rotation of the business and the compositional change of that business as we moved away from international because borders were closed for the most part and focused on Thai business, ex pat business and some international business that we did experience in Q2 on an emergency medical treatment basis, which generates revenue in a particular category called alternative hospital quarantine, and we'll talk more about that in a moment. But you're going to be able to see this quarter how it is that we're generating this kind of revenue just essentially looking at business in Thailand. So let's talk about the top line key takeaways of the quarter. For the quarter, the quarter over quarter revenue was 12.8%. There was very, very strong support both from COVID revenues amongst Thai people, expats. And you will see when I go through this, the additional level of detail, which mattered to about a 25% increase of alternative hospital quarantine patients. And these were ill patients that came in internationally. But as you know now, in Q3 forward, the borders are completely shut. So there's no one bringing in any international patients, and that includes us. The presenters today is especially Daniel and Kunwissut, our Digital Marketing Officer, are going to go through the level of details that drove this 12.8 percent revenue increase. And just on the Thai business alone, the amount of additional incremental revenue Q over Q was 171,000,000 baht, and that came from a variety of different programs, not only COVID treatments and COVID screenings, but it also came from online and offline digital platforms. In addition, we launched our own version digitally of a Moderna vaccine program rollout, for which in the end we purchased an advanced purchase and advanced payment a little over 17,000 jab vaccinations, which we'll be receiving in the middle of Q4 sometime as we are told by the government pharmaceutical office, which is a subentity of the government. That entire allotment is sold out in advance, and we'll administer that in Q4 and rolling into Q1 2022. So let's get into some level of the detail on the business for Q2. For the overall market, I've mentioned 12.8% quarter over quarter. While not meaningful in terms of a comparative nonetheless from Q2 2020, the growth was quite significant, but not of use in terms of comparing because they're really not comparable. Next slide. So then now if you look deeper into the tie revenue, you can see the chart below. But you can see for the Thai revenue, it increased quarter over quarter 12.1%. And when you look at the numbers inside that percentages, from COVID Business, meaning screenings, meaning treatments, the amount of revenue generated was an incremental $95,000,000 The amount of online revenues increased by $23,000,000 Increase in our telemedicine services was 20,000,000 baht and then others was about 34,000,000 baht. And Daniel later is going to talk about that level of detail. Next slide. Similar story for expats. The growth for Q2 is up 7.2%. Again, on the quarter, a pretty significant growth and of course, a significant growth over 2020. When you look deeper into what the 7.2% entailed, it was about $34,000,000 again, related to COVID screenings and treatments. Online revenues, almost $9,000,000 and then all others made up the difference. When you look at the nationality, so when you think about expat for us, there's 2 types of nationalities. You have all those except Middle Eastern nationalities and then you have all other. So for us, all other in the quarter, we saw significant growth. Bangladesh was up 11% Germany, these are by nationality. Germany, up 9.7% Japan, up 9.5% the United States, up 9.3%. When you look at the net revenue growth, Japan was number 1 at almost 30% growth quarter over quarter for the I'm talking about 2020 versus 2021 Australia, almost 17% India, 13%, etcetera, etcetera. So we had strong broad year over year growth, of course, but very strong quarter over quarter growth. And you can see the monthly performance, the green line versus the dark line. Next slide. So this is all international. So this is everything that we define all international, which includes all of it. And the growth was almost 19% quarter over quarter. Recall now that this includes HQ revenue that was fairly substantial in the quarter because it was still allowing emergency international patients in. And this is, as an example, Indo Chinese patients and others. Can we show that detail? Next slide. So when you look at what drove some of those numbers on the growth percentage, you can see by nationality and country Kuwait, Qatar, Myanmar, Mongolia. And the first three, while these are percentages, when you look at the revenue behind them, they were fairly substantial. And we still maintain a fairly good volume of business from Middle Eastern patients, those that have been here and a few that do trickle in. And then the rest, you can see the distribution. Bangladesh was pretty strong in the quarter, Bahrain, Oman. But on the larger volume related revenue, the top 3 are with the most significant contributors on revenue, especially Q over Q and in some cases, year over year for the quarter. So total international was up almost 19% for the quarter. Again, when you look at the distribution of contribution of the revenue drivers, this was an important one for us too beyond Thai, beyond expat. Next slide. Middle East, again, another major contributor to our revenue base quarter over quarter, almost up 25%. Against Q2 '20, it's going to be less because the borders at some portion of Q222 'twenty, there was more of a free flow beginning to starting to close down. But against Q1, it was substantially higher because we were able to bring in patients who were quite ill and approved by the Ministry of Public Ministry of Public Health. Next slide. Indochina, very much a similar story. Strong uptick in revenue over quarter, 28.3% from Q1. And the year over year change was very, very high because by that time, Myanmar was just about shut, although there are other parts of Indochina, Cambodia, Lao, etcetera, and I'll show you that. Next slide. So on a consolidated basis, when you look at HQ and ASQ performance for the quarter, you will see that for the HQ, dollars 536,000,000 for Q2, $428,000,000 for Q1 2021, and that represented about 25%. More importantly, when you look over to the right, you'll see a conversion of 67%. And as I've explained in the past, there is revenue generated that is associated with being in the AHQ, which means quarantined for 10 to 14 days depending. And there's some revenue generated there, but the 67% has to do with, in addition, revenue that is generated by those patients who then use our inpatient and outpatient facilities. In a similar way, although more transitionary, you have the ASQ, where the conversion rate for the quarter was 16%. In Q1, it was only 10%. So that rose as well for the quarter for us. All of the indices on revenue drivers, on market drivers, on digital platform drivers, we're all striking a very, very positive ability to drive revenue in the quarter and as a result drove us up to almost 13% quarter over quarter performance. Okay. Please go back to the highlights. So as we look at expectations going forward, the latest information that we hear and see through governmental agencies, through government sponsored organizations, through commercial banking expectations, specifically Bank of Thailand and Tourist Authority of Thailand. They are guiding that given the huge surge in COVID patients, meaning infections, case rates, infection rates, death rates, given the current rising orientation. And just today, we saw that it was a record high, 20 over 22,000 infections yesterday in Thailand, a reasonably good portion of them in the Greater Bangkok area and provinces surrounding Bangkok. There is a high level of uncertainty, low consumer confidence, high savings as a result of people not wanting to spend money, wanting to husband money, because I'm sure where this is all going. So for us, when we look at what used to be the biggest portion of our business, which was international, we're really not expecting that to return to any level of normal performance until sometime in 2022. When that is in 2022 will really depend upon the government vaccination program and the availability of additional vaccines being brought into the country, which, as you know, media has reported that it's been slow in coming into the country and also slow in its distribution. But many of the experts expect that change and get better as we move into Q4 and beyond. But that's a major limiter to how it is that the country will open up. Firstly, the sandboxes, both in Phuket, although it's it has opened up, it's been slow. Samui is just about to open up, but slow. Need to bend that curve downward in the number of infections in order to create stronger consumer confidence. But in the meantime, we as a company recognize this because we're looking around the world and looking at surges and watching how it is that these surges continued growing upward with higher and higher infection rates and then declining as the curve was bent downward, we anticipated that we'd have to focus on the business at hand, which is what we have in Thailand. And now even in the Q3, with the borders now shut, we even have to be more reliant on the business here in Thailand, and we're prepared to do that. I think Q2 showed you, as investors and interested people in our company, that we've been quite successful at doing that. At our Board meeting this past week, our Board of Directors looked at the different possibilities and variations on the interim dividend payment and it being a strong value company with strong cash reserves, the Board on Wednesday evening approved a dividend payout on EPS of about 300% of EPS and the amount is a little over 900,000,000 dollars but and that will be paid in the early part of September to shareholders of record. A strong commitment once again to our shareholders owning shares in our company. As of the end of July, the company was in very strong position, having 8,300,000,000 baht in cash. And of course, those who follow us know we're in a negative debt situation. 4Q3 guidance, with almost 13% growth in top line revenue, it's uncertain about where we will be in Q3 and Q4, strictly predictable and driven by the number of infections, the rate of the lockdown, the extent of the lockdown, the duration of the lockdown, but we will continue to execute to our offline and digital platform to drive supplemental revenue for those people that are concerned about coming into the campus. And of course, there'll be revenue driven by unfortunately, at least at this point in time, will be driven by COVID screenings, COVID treatment and vaccinations, which we're very, very much focused on, which you'll hear a great deal more about how we're driving our orientation as we look at our business composition having been different really over the last 2 to 3 quarters. Thank you. Good morning, everyone. I'm Chitima Nantawichita Poon, DuPity's CFO. I am pleased to report the financial performance of the Q2 twenty twenty one and the first half of twenty twenty one. First, financial highlights. Despite the surge in COVID-nineteen cases in Thailand in mid December 2020 and continuing into 2021, the Thai and expat business continue to grow year on year. Restrictions on travel and medical tourism continue to impact the company's international business, especially when compared to the first high base of the first half of the first quarter of the previous year when COVID-nineteen was only marginally impacting the company's performance. The Q2 of 2021, revenue increased by 23.2% year on year. This was mostly due to an increase in revenue from Thai Patient by 27.3% and non Thai Patient by 18.5%. EBITDA increased by 81.7% with EBITDA margin of 19.1 percent, increased from 12.9 percent in the Q2 of the previous year. Net profit and diluted EPS increased significantly by 387.2 percent with the net profit margin of 7.2% compared to 1.8% in the Q2 of 2020. The Q2 2021 performance improved from the first quarter 2021, primarily due to the increase in revenue from Thai expat and international patient from alternative hospital quarantine service. Revenue increased by $12,700,000 from Q1 and net profit grew by 137.5%. For the first half twenty twenty one, revenue decreased by 13.5% from the previous year. EBITDA down by 36.6 percent with EBITDA margin of 17.3% compared to 23.6% in the first half of twenty twenty. Net profit decreased by 62% with net profit margin at 5.4% in the first half of twenty twenty one compared to 12.3% in the first half of twenty twenty. The decrease mostly attributed to the limited impact of COVID-nineteen during the Q1 of 2020. Move on to financial performance. The company reported total revenue in the Q2 of 2021 of 3,020,000,000 baht. This amount represented a 23.2 percent increase from the Q2 of last year. For the first half of this year, total revenue was KRW 5,694,000,000, a 13.5% decrease year over year. This was mostly due to a decrease in revenue from non Thai patient by 32.3%, offset with an increase from Thai patient by 13.1%. Revenue contribution by nationality. As restrictions on travel and medical tourism continue to impact the company international business and our continued marketing for local market, The percentage of revenue from Thai Patient increased to 54% for both second quarter and the first half of twenty twenty one compared to 52% in the Q1 of 2021 and forty one percent in the first half of twenty twenty. Revenue contribution by services. For the Q2 of 2021 2020, the proportion of revenue from inpatient services and outpatient services was the same at 52% 46%. For the first half of twenty twenty one, the proportion of revenue from inpatient services slightly decreased from 54% to 53%, mostly due to a slight decrease in average length of stay for non tight segment. Revenue contribution by payer type. There was a trend in payer mix due to COVID-nineteen pandemic impact. The government third party payer contribution was reduced from 19% last year to 11% for the first half of this year due to restrictions on travel and medical tourism for Middle East Business. Sales pay also was increased from 60% to 64% in the first half of this year, mostly due to an increase in Thai and expat sale pay. Insulin contribution also increased from 19% to 22% in the first half of twenty twenty one due to an increase in Thai and Expat Insulin Business. EBITDA was BRL 576,000,000 in the Q2 of 2021, increased by 81,700,000 baht in the Q2 of 2020. The increase was mostly due to the increase in revenue and also our cost management programs related to workforce management, contract management and inventory management. EBITDA for the first half of twenty twenty one was BRL 986,000,000, a 36.6% decrease from 1555,000,000 baht in the Q1 of last year. The decrease was mostly attributed to the limited impact of COVID-nineteen during the first half of twenty twenty. EBITDA margin was 19.1% in the Q2 of 2021, increased from 12.9% in the Q2 of last year. EBITDA margin was 17.3 percent for the first half of twenty twenty, decreased from 23.6% in the first half of last year. Net profit for the Q2 of 2020 was BRL 216,000,000, increased by 387.2 percent from BRL 44,000,000 in the Q2 of the previous year. Net profit for the first half of this year was bah 308,000,000, a 62% decrease from bah810,000,000 in the first half of twenty twenty. Net profit margin was 7.2 percent in the Q2 of 2021 compared to 1.8% in the Q2 of 2020. For the first half of twenty twenty one, net profit margin was 5.4% compared to 12.3% in the first half of last year. Net net to EBITDA was 0.6x for the first half of twenty twenty one, slightly higher than year 2020 due to less EBITDA in the first half of this year. Net debt to equity was 0.1x as of June 2021, almost the same as December 2020. Interest covenants ratio was dropped to 15.1x due to less EBITDA. However, when consider bond covenant requirement, which required to have net debt to EBITDA at less than 3.25x and net debt to equity at less than 1.7x, the current net debt to EBITDA and net debt to equity for the first half of twenty twenty one still a lot lower than the bond covenant requirement. Thank you, Thank you, Konjitima. I'd like to start off with the business updates with the Q2 2021 snippets. This is essentially a new way for us to present some key numbers during the quarter, which we believe would be of interest to you. Let's start off with the first item. You may notice that under the OneCard direct accretive revenue, this is essentially revenue generated directly incrementally from new and existing reactivated patients. And what we mean by that is reactivated patients being people who have visited the who have not visited the hospital over the last 2 years, having once again used services at Bamumrad BHPCL. The OneCard is essentially a partnership loyalty program between Central Group and ourselves and it has proven to be very successful in driving additional spending and incremental revenue to the hospital, we calculate approximately BRL 291,000,000 in revenue generated in the Q2 2021, which is a growth of 27% Q on Q or 2,930 percent year on year. And the reason for that large growth number is from the is due to the start of the program in May of last year. So due to that, the low base effect, you need to take into account as well. The other channel which was significant during the quarter were referrals from other hospitals, generating approximately CHF 211,000,000 in revenue. Referral from other hospitals includes hospitals that are under the Bamumrad Health Network and from other local hospitals within Thailand who have referred either complicated cases or overflows to Bamumrad Hospital itself. This number continued to grow and has continued that trend over the last several quarters already, generating 39% Q on Q in growth and 21% year on year in growth. Something that many people would be interested to know is COVID-nineteen revenue. So revenue generated from COVID related treatments and screenings amounted to approximately TRY 198,000,000 during the quarter, a growth of 321% Q on Q or 3 72% year on year. The growth has been significant and is in direct proportion to the number of new COVID cases that we are currently seeing during the 3rd wave, which continues still unabated since May. Onto Telemedicine and Home Care revenues, that amounted to SEK 115,000,000 during the quarter and continued to grow quite strongly, up 31% Q on Q, 11% year on year. The telemedicine and home care services has grown quite well given the reluctance of people to seek health care on premise at the hospital, we have therefore digitally engaged with the patient through telemedicine and home care services and that demand continues strongly. On online store and digital products, these are essentially products we sell on our online store, both in the website and through the Bamumrad app. These include packages such as screenings and other ancillary products, which we are selling online and digitally. These products have shown remarkable growth, 6 18% Q on Q or over 1,000 sorry, over 103% year on year. The online store is a relatively new development, which only begun to take root since the beginning of last year. And we've been very proud and pleased with the uptake of this channel in driving revenue growth to the hospital. Onto the COVID-nineteen vaccination program, the hospital has received very good feedback from patients who have received vaccinations both government provided and also privately funded vaccines such as Moderna. We've also begun to organize inoculations for the Pfizer vaccines that have been received thanks to the generosity of the U. S. Government for health care and frontline medical care workers. Some of these have been also allocated to expats, and we have also begun to organize bookings for expats as well. I'd like to show you a clip on the vaccination, and these have been designed specifically for Japanese expats. In addition to providing vaccinations, we have also opened the opportunity for patients to buy checkup packages under the very popular buy 1, get 1 free campaign. This was again reinitiated during the June, July period to sell packages to people coming for vaccinations. And as you can see, it generated approximately BRL19.5 million in additional revenue for the hospital amounting to 801 packages. During the quarter, we also launched 2 key clinics, the Pride Clinic, essentially providing transgender or sexual reorientation services to patients seeking those services. These are rather extensive, not only surgical, but includes multidisciplinary approaches to treating and preparing patients for these kinds of surgical procedures, hormone therapy and other areas which we hope to continue to expand. The market is significant not only within Thailand, but also targeting international patients, specifically in China, where we see a large number where we see high demand from patients. And we expect that once the country opens up, we can tap into this high growth area. Secondly, the allergy clinic, which we have already established, but we have enhanced with services related to home care and treatments. These are just a few slides of the launch of the Pride Clinic, which was very well received by the public. On to our target in how we in terms of its in terms of in terms of its in terms of the continued travel restrictions that we have in Thailand. So our focus continues to be on the Thai and expat segment. And what are we doing in growing that area? We're looking at expanding our digital connections with our patients through social media, through content, in growing awareness and demand for health care related issues. We are observant of the fact that throughout the world due to people's reluctance to come to hospitals, a number of underlying health issues will start to take will start to take increasing prominence in terms of their effects on people's health due to the lack of health screenings, due to a lack of follow ups with physicians, etcetera, and also the lack of activity at people's homes. And as a result, we continue to want to engage with our patients in highlighting underlying health issues that may continue to affect them during this time of lockup. On to the expat market, as you can see, we've targeted 4 key categories of expats: the Japanese expat market, the American expat market, the Chinese expat market and the Indian expat market. All 4 have specific key focuses, as you can see on these slides. For Japanese, OBGYN, Sports and Joint, on Chinese, oncology and also IVF as is well known to be in high demand. For the Indian market, which is significant in Thailand, oncology and colorectal are key areas of focus. And for American expats in general, OBGYN and also oncology as well have been key focuses for us. These are areas of significant strength for us, and we expect to continue to utilize these to further penetrate those markets. And as you will see or as you have seen, the growth in the expat market has been rather encouraging during the quarter and has continued to be the case since the previous quarters as well. So that concludes my part of the business updates. The next part will be presented by Kunvisut, our Chief Digital Martech Officer, who will provide us with exciting updates on what we are doing in this area. Kunh Wissut, please? Hi, everyone. I am Wissut Yoo Anand Nakap, Chief Digital MarTech Officer at Baumlunga, Nakab. Today, I would like to update you about the MarTech work for Q2, Nakab. First one, about BH Online Store, Nakab. This is the 2nd year of the online store, Nakab, that we did, Nakab. And clearly, we have more than 349 package sale from 42 clinic in online store. We still have more clinic in Bam Lung LAD. We have more than 60 clinic. We can add more in the future. The approach that we did for the online store, it's totally different from the competitor. We use the approach that call direct to consumer approach. What it means for this? The direct approach, direct to consumer approach is mean all the data is going to collect by us. And this year, I used the data from last year to retargeting the customer for this year. And also, we have the order 360 view of the behavior of customer that we can find the package more and look alike model to find more customer to buy as well, the cup. It's totally different from the competitor that use Shopee, Lazada to sell package. That way, it means all the data belong to that platform, the car. They cannot do like us, the car. That's why they have to use the platform from Lazada and Shopee. And we did all of this in how development in Bam Lunga for the whole thing. Okay. Let me continue with. Clearly, we already have the vaccine store. This is the example. Vaccine store, we have women's center. We have children's center specifically for each clinic and each package for the customer. And we also have the nutrition and also tailor consultant for nutrition package in here. And this one, Genetics Store. Genetics Store is the new store that we also did the new promotion with Inturan. Inturan can redeem the pipe and use the point to convert to be the discount code to get the genetic for free. Currently, our online store support for exchange the point, exchange the discount code with the partner. Okay. For this one is the revenue. This one, last year, Online Store, we launched for the 1st year. We got KRW 36,000,000 in 36 day on that time when we have the Buy 1, Get 1 campaign. For this year, you can see April May is growth because we have Buy 1, Get 1 campaign on that period. For June July, we not have the Buy 1, Get 1. But we still can maintain the revenue growth from after that, I will show you what is the reason we can make it grow, Nakab. But this year, Nakab, we can make 65,000,000 in 45 day, Nakab. It's more than 100% from last year. And we also make the overall for our online store until July is more than 100,000,000 already. This one, we achieved more 100% of the total year last year. Okay. This is the new feature that we did, Nakab, on July, Nakab. We integrate with the One Point, Nakab from the One Point to convert to be the redemption discount, for the online store. And people also earn the payment that they pay in here to be the point of the one as well. We already make this one happen in online. And okay, this one is the one that incredible thing for me. You know in I did online store in many company, but I never see that I can sell like a 500,000 baht gift card. But I can make this thing happen in Bam Lungkang right now. And we sell the best selling as well, Nakkang, for this one, Nakkang. This one, that's why we can maintain the revenue growth from the gift card, 500,000 Bahtang. And we offer right now, if people buy 500,000 baht, they can get 25,000 increase for their purchase more. Totori for the revenue clearly is more than KRW 63,000,000 from gift card that we did. And you can see for the 500,000 baht value, just only 1 month, we can sell 37 package in 1 month. We just launched this one in July. And for the you can see the online, offline part. Online is the 49,000,000 and offline is 30,000,000. Off line is mean we have we also have the physical gift card, Nakab, that sell in off line, Nakab. And people can come to here to buy the physical gift card and give it to the patient in the IPD room, something like that, We did this concept is the new innovation concept that we are the 1st in Asia in hospital that we have the gift card to send the new normal way to visit the patient. We can send via live as well clearly. And we also send via e mail via chat, any chat that we can send right now, Nakab. Okay. For application, Nakab, VH application, currently, we have 58,000 people active use our app right now, Nakhap. You can see we have incredible growth. In one day, we can grow more than the whole year, Nakhap, because we did the my vaccination record, that people can check about the vaccine, what is the first injection, the second injection, something like that. And people have to link the HN with the backup security, to see their own patient information. You can see we have the Android and iPhone. And we have iPhone more than Android. It's 70% and 30% is about Android. Nakab. Okay. The next one, Nakab. The next one, I update you about the feature that application did, Nakab. We have the new feature 6 features, Nakab offer and voucher. Okay. I will show you how it is, Nakab. Actually, it is indicated with the online store. When you purchase anything voucher from online store, it will automatically link the voucher to the application. You just come to here and open the application. You can scan the barcode and treatment line away. After your treatment, you can go back home. No need to go cashier anymore because you already paid for the online store. And we also have the birthday discount code 10%. This one, we offer we use the database of the Bunlong Lar. And every month, we will have the people who birth on that month, we offer 10% discount for them in online store. But they need to use application only to get this voucher, to endorse them to use our application more, and we can retargeting them as well. And My Vaccination Record, the 3rd one, is a new feature that we did and a really success. And people load our app more and more, and use every day. And they're going to keep this information for the whole life, Nakap. Because if you want to know your first injection of vaccine, second injection of vaccine and another vaccine, you need to click on this menu, Nakap. And also we can offer the additional vaccine in the future to via this menu as well. The 4th one is about recommendation packet. I will show you how it is. And 5th one is about keyword suggestion for doctor search. Right now, we make the better search for doctor, Nakab. You can search in specialty, last name, first name. You can search organ. You can search symptom condition treatment, all the thing, And the last one is about LINE official account. Currently, Thailand use the most the second in the world to use LINE. That's why we support LINE chat via our application as well. Okay. Let's see detail. The first one is about offer and voucher. This one integrate with the BH Online Store part. When people buy anything from online store, the history of purchase will go inside the application. And application, we will have status to tell that it's active, it's used, it's expired to remind the customer as well. And we also have the birthday campaign in here. That on your birthday, birth month, right, you're going to get this voucher, and it's going to remind you to use it to discount the 10%. Okay. The second part, this one is about the voucher, the history of voucher and the status of voucher, any voucher that you purchase, Nakap. You can use the barcode to scan in hospital and treatment right away, Nakap. And it also have the chair icon, Nakap. Right now, we make any purchase of the voucher, you can make it chair to anyone you love, Akab. You can share to your family, your friend. You can share to anyone. We have any channel, because similar to the bank account. When you transfer bank account, you cannot save the picture of the transfer to the phone, right? You can forward that picture to anyone you love. But this barcode can use only one time in here. This is a new way to make every voucher as a gift. Okay. This one is the highlight one for the application this year. It's my vaccination record. You can see that all people are concerned about the problem, right? And are concerned about the death that to inject the vaccine, the first chart, the second chart, right? Maybe the third chart or the first chart. We already made this thing happen for the Bam Lunga. And you can see it's not show only the COVID vaccine. It show every vaccine that you inject in Vamilong Lan. And it have the date and time to tell you. In the future, it can make like a passport for you that you already have, which vaccine you already have, Nakab. You can see it show all the vaccine that you have in Bam Lungla, Nakab. It's automatically show in here. Nakab. Okay. For this one, Nakab is about the keyword, suggestion for doctor search. Nakab, You can search the doctor name, last name, specificity, subspecificity, symptom, disease and keyword. It's the suggestion, and you can find the doctor easier. And you can click on the doctor. Clearly, you can make appointment, Nakab. In the future, you can make telemed appointment as well. Okay. Next one is online integration, Nakab. For the application in the application, Nakab, we have live, we have Facebook Messenger, WhatsApp. And we can make call. We can make appointment into the application. We also support live, and we're going to support all the chat. That's support for each country in Nakab because we design this application not only for Thai, but we design for the global Nakab. Okay. This is the new feature that's going to happen on the 26th August, Nakab. We will have the BKI free insulin for COVID vaccine. We cannot have the Japanese language support. We will have the podcast section. We will have the dynamic appointment confirmation. And we will have the telemedicine indication. The first one, BKI. This one, anyone who going to come to Bam Lungla and inject the COVID vaccine, you can come to our app and click on the BKI and fill the form. You're going to get the free protection for the vaccine. If you have some effect with the vaccine, BKI will support you. This one going to happen on 23 August. And this one is the Japanese version. We support Chinese people because we got the vaccine from Embassy, Japanese Embassy to come to inject to Bamleng Nang. And we want them to have the version of Japanese to help them and the vaccination record to help the Japanese people as well. We currently, we have English, Thai and Japanese. We will have the Chinese and Arabic soon. This means we're going to support almost all the target customer that we have in Bamumeng Rat currently. It means that you can when you drive a car, you can listen the podcast of the Belongart in car. We have this section up for the 23rd August as well. This one is the feature of telemedicine integration. We already have the telemedicine for follow-up clearly. And we will have the appointment reminder. We will have the telemedicine reminder in here. And people can click on the application to talk with the doctor right away, Nakab. This is the old version of our telemedicine. We will have the new Telemat on demand. It's going to happen in next month, Nakab. Okay. This one is about ePayment system, Nakab. This is the new enhancement of e payment. We launched on the 16th June. Currently, people don't want to come to hospital because they worry about the COVID. We have the way to send the e payment link to them anywhere in the world. And they can kick the ring to make payment for family or for yourself or for anyone. We have the many options. Currently, we did our own payment system. And we can open and we can turn on, turn off for the any payment gateway in here, Nakab. We not do only 1 payment gateway. We're going to do 4 multiple payment gateway in here, Nakab. And you can see we will have PayPal. We have AmEx coming soon. We also did we payment gateway from Asian for further growth, tourism for further whole Singaporean, other thing. We already integrate in our e payment system as well. This one already support for future. Okay. This one is about the way you chat to the contact center, And we also add the chat to the expert, chat with nurse, Nakab, and to the clinic specifically, Nakab. We can have the landing page specifically for heart, for any specific clinic. And people can click to consult with the expert and chat directly to the nurse, Nakab, with our new system, Nakab. And we build AI on top to become like a chatbot, to try to find FAQ, frequency ask question first. And if that one cannot answer, it will forward to the right people. And it's also linked to the CIM case management part that we have SLA to answer the customer. This feature also available for any chat of the Wamunnga and also on the VH application. Okay. We already load out with the COVID center team, information team, Nakab. If anyone have the question about the vaccine, about the COVID, they can come to our chat and ask Nakab. And we have the mascot to be the chatbot Nakab currently. Okay. This is the look and feel of chatbot do Nakab. This is just version 1 Nakab. Actually, we already prepared our chatbot already support Thai, English and Chinese nakap. We're going to make a support for Japanese and Arabic nakap later nakap. Okay. That's all kap for me, kap. Thank you, kap. Thank you, Kunwissot. And that concludes our Q2 2021 analyst presentation. Stay tuned for the live Q and A session for those who are invited on the 19th August. We will be posting this presentation to you on the 17th August, so you will have plenty of time to review and ask us any questions you may have. As usual, you can always contact us through all the regular channels. Thank you.